News

Latest news

9th May 2023

Newton Biocapital was pleased to contribute to a comprehensive analysis of the life sciences ecosystem by Tatsufumi Aoyama of the Development Bank of Japan

Read more
2nd May 2023

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Read more
26th April 2023

Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023 Publication of Annual Report 2022

Read more
7th April 2023

Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy

Read more
3rd April 2023

Newton Biocapital 3rd Annual Recital & Networking Cocktail Flagey

Read more
24th March 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Read more
22nd March 2023

Nikkei Bio Article: AMED's Drug Discovery Venture Ecosystem Enhancement Project Selected for the First Time by Two Companies - Edit Force and Immunohelix

Read more
22nd March 2023

EditForce, Inc. announced that our "Development of an Innovative Treatment for Myotonic Dystrophy Type 1 by a Sequence--Specific RNA Binding Protein Targeting Pathogenic CUG Repeat

Read more
22nd March 2023

EditForce, Inc. (Headquarter: Fukuoka, President and CEO: Takashi Ono) announces that we have raised a total of 1.8 billion yen through a third-party allotment of new shares by March 22, 2023.

Read more